Protagonist Therapeutics Inc

NASDAQ:PTGX

51.05

+0.36 (+0.71%)

4:20:00 PM EDT: $51.05 0.00 (0.00%)

Market Cap (Intraday)	3.19B
Current PE	56.71
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$7.51 Million
Adjusted EPS	-$0.58

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Protagonist Therapeutics Inc Stock, NASDAQ:PTGX

7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160

United States of America

Phone: +1.510.474.0170

Number of Employees: 126

http://www.protagonist-inc.com

Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.